Preservation of genome integrity via the DNA-damage response is critical to prevent disease. ATR (ataxia telangiectasia mutated- and Rad3-related) is essential for life and functions as a master regulator of the DNA-damage response, especially during DNA replication. ATR controls and co-ordinates DNA replication origin firing, replication fork stability, cell cycle checkpoints and DNA repair. Since its identification 15 years ago, a model of ATR activation and signalling has emerged that involves localization to sites of DNA damage and activation through protein–protein interactions. Recent research has added an increasingly detailed understanding of the canonical ATR pathway, and an appreciation that the canonical model does not fully capture the complexity of ATR regulation. In the present article, we review the ATR signalling process, focusing on mechanistic findings garnered from the identification of new ATR-interacting proteins and substrates. We discuss how to incorporate these new insights into a model of ATR regulation and point out the significant gaps in our understanding of this essential genome-maintenance pathway.
- ataxia telangiactasia mutated- and Rad3-related (ATR)
- ATR (ataxia telangiactasia mutated- and Rad3-related)interacting protein (ATRIP)
- DNA-damage response
- DNA replication
Safeguarding against unfavourable changes in the genome during cell division is vital. Although packaging DNA in chromatin may protect it, genes need to be transcribed, and chromosomes need to be duplicated and segregated. Thus, even for normal DNA metabolism, DNA is precariously unwound, nicked, copied, broken and recombined. The cell also produces reactive metabolites and oxidation products that damage DNA. Finally, exogenous sources of DNA damage such as radiation and other genotoxins are prevalent in the environment. This combined assault on DNA yields tens of thousands of DNA lesions per day in every human cell.
In response, the cell mounts an evolutionarily conserved DDR (DNA-damage response) that co-ordinates cell-cycle progression, DNA repair, DNA replication, DNA transcription and even cell death to promote genome maintenance. Mutation or deletion of many DDR genes results in lethality, cancer-susceptibility syndromes, neurodegenerative disorders and premature aging syndromes. Therefore genome maintenance via the DDR is essential to prevent disease.
At the apex of the DDR are three related protein kinases, ATM (ataxia telangiectasia mutated), ATR (ATM- and Rad3-related) and DNA-PK (DNA-dependent protein kinase). These kinases belong to the PIKK (phosphoinositide-3-like kinase kinase) family and share similar domain architecture and several modes of regulation [1–3]. Whereas DNA DSBs (double-strand breaks) activate ATM and DNA-PK, many types of DNA damage activate ATR, including DSBs, base adducts and cross-links . Once activated, these kinases preferentially phosphorylate serine and threonine residues followed by a glutamine residue (S/TQ) in hundreds of protein substrates. In some cases, substrates contain multiple phosphorylated S/TQs within a small region of the primary sequence-S/TQ cluster domains [5,6].
The most common signal for ATR activation probably involves replication stress (interference of replication fork progression caused by DNA damage, lack of sufficient deoxynucleotides and even difficult to replicate DNA sequences). In response to replication stress, ATR regulates replisome stability and origin firing and prevents premature mitotic entry . ATR, unlike ATM and DNA-PK, is essential in replicating cells [7–9]. This probably is due to ATR activation by replication stress in every S-phase and perhaps regulation of specific aspects of DNA replication such as origin firing or nucleotide production. Failure to resolve stalled replication forks results in unreplicated DNA, ssDNA (single-stranded DNA) replication intermediates and DSBs. ssDNA and DSBs are highly recombinogenic, and aberrant recombination of these structures yields chromatid- and chromosome-type errors [10,11].
Homozygous loss-of-function mutations in ATR are not compatible with mammalian cell viability [7–9]. However, hypomorphic mutations in ATR that cause reduced ATR function are found in a few patients with the rare Seckel syndrome, which is characterized by microcephaly and growth retardation . In certain genetic backgrounds, ATR is a haploinsufficient tumour suppressor [13,14], and ATR mutations in microsatellite instability tumours are associated with reduced overall survival and disease-free survival [15,16]. Oncogene-induced replication stress activates the ATR pathway, explaining the high levels of DDR activation in many neoplasias [17–19]. Therefore the ATR pathway and the DDR potentially constitute a barrier to cancer . Bypass of this barrier may be a double-edged sword for the cancer cell, as cancer cells may exhibit an increased dependency on the ATR pathway, analogous to oncogene addiction, to continue to replicate in the presence of oncogene-induced replication stress. Many current therapies are DNA-damaging agents that increase the signalling burden on the ATR pathway, and ATR pathway proteins may be good drug targets in cancers containing elevated levels of replicative stress.
Canonical ATR signalling
Replication stress often results in the generation of excess ssDNA through uncoupling of enzymatic activities at the replication fork. For example, many DNA lesions stall the DNA polymerase, but not the replicative helicase . Whereas lesions, such as ICLs (interstrand cross-links), block both the polymerase and helicase, enzymatic remodelling of the blocked replication fork by helicases and nucleases also creates ssDNA. Similarly, nuclease-mediated resection of DNA DSBs produces ssDNA . ssDNA is bound by the ssDNA-binding protein RPA (Replication Protein A). In the canonical ATR signalling pathway, RPA–ssDNA is the ligand that recruits ATR and other ATR signalling components to sites of replication stress. Once RPA–ssDNA appears, ATR signalling canonically requires: (i) recruitment of ATR via its obligate partner ATRIP (ATR-interacting protein) to RPA–ssDNA; (ii) independent recruitment of a checkpoint clamp, containing RAD9–HUS1–RAD1 (9-1-1) proteins, and the ATR activator TOPBP1 (topoisomerase-binding protein 1) to RPA–ssDNA; (iii) activation of ATR by TOPBP1; and (iv) phosphorylation of ATR substrates (Figure 1). Cases where ATR activation occurs independently of steps (i)–(iv) and RPA–ssDNA are defined as non-canonical for the purposes of the present review. For a more detailed description of the canonical pathway, we refer the readers to an earlier review . In the present article, we review new advances in understanding each of these steps in ATR signalling, emphasizing novel ATR regulatory factors, ATR targets and non-canonical pathways of ATR regulation.
THE ATR–ATRIP COMPLEX
Of all the identified ATR-interacting proteins, perhaps only ATRIP is obligatory for all known ATR functions. Deletion of ATRIP in yeast and silencing in mammalian systems phenocopies loss of ATR, resulting in lethality, DNA-damage-sensitivity and abrogation of ATR substrate phosphorylation [7,23–25]. ATRIP has at least three well-defined functions in ATR signalling: regulating ATR stability, localization and kinase activation. The stability of ATR and ATRIP are mutually dependent , consistent with the formation of a stoichiometric complex. Indeed, ATR and ATRIP stably associate independently of DNA damage [26,27]. ATRIP binds directly to RPA to promote accumulation of ATR into damage-induced foci [26,28]. Finally, TOPBP1 activates ATR through a direct interaction with ATRIP [29,30]. In addition to these clearly elucidated functions, there are several additional ATR signalling regulators that may depend on ATRIP for their effects.
ATR and other PIKKs, including ATM and DNA-PK, associate with TEL2 . Initial results suggested that TEL2 regulates the stability of these kinases. However, unlike ATRIP, TEL2 does not co-purify stoichiometrically with ATR, suggesting a more transient interaction. Recently, several groups determined that TEL2 functions as part of multiprotein complexes that include protein chaperone activities [32–35]. TEL2 binds TTI1 and TTI2 forming a Triple T complex, which also contains HSP90 (heat-shock protein 90) [33,34]. TEL2 preferentially associates with newly synthesized ATR within 1 h of synthesis and not after. In the absence of Triple T/HSP90, newly synthesized ATR is unable to co-immunoprecipitate with ATRIP. Thus it is likely that the Triple T/HSP90 complex promotes the correct folding of ATR and other PIKKs to allow their assembly into proper protein complexes. TEL2 also facilitates PIKK maturation through the R2TP–prefoldin-like complex . Thus, in the absence of TEL2, newly synthesized ATR is not properly folded and assembled with ATRIP, explaining the checkpoint defects that are associated with TEL2 silencing. The PIKKs are very large proteins with extensive HEAT repeats. HEAT repeats typically do not form globular domains. Instead, they create extended surfaces that mediate protein and DNA interactions. This architecture may explain the need for these chaperone complexes for proper folding and assembly.
CINP and CEP164
Although all eukaryotic organisms have an ATRIP, the amino acid sequence is highly divergent to the extent that the vertebrate ATRIP could not be identified through homology with lower eukaryotic proteins. Despite this poor sequence conservation, the overall architecture of the protein is conserved, with an N-terminal RPA-binding domain followed by a coiled-coil domain and a C-terminal tail that includes the ATR-binding region (Figure 2). The ATRIP coiled-coil domain is required for ATRIP dimerization and stable association with ATR [36,37]. Disruption of the coiled-coil domain perturbs ATRIP localization to foci and ATR signalling to CHK1 (checkpoint kinase 1) in mammalian cells. Replacement of the ATRIP coiled-coil domain with a heterologous coiled-coiled domain restores some, but not all, of ATRIP's functions . These data suggested that the ATRIP coiled-coil domain might mediate a protein–protein interaction important for regulating ATR signalling. A search for proteins that interact with ATRIP through the coiled-coil identified CINP [CDK2 (cyclin-dependent kinase 2)-interacting protein] . The function of CINP in ATR–ATRIP signalling is not yet clear, but CINP silencing causes modest defects in ATR-dependent CHK1 and SMC1 phosphorylation, HU (hydroxyurea)-sensitivity and loss of the G2 checkpoint. Since CINP does not appear to form foci with ATR–ATRIP or alter the in vitro activity of ATR, it may function through a transient protein–protein interaction that facilitates modifications of the ATR–ATRIP complex in cells. G2 checkpoint defects in CINP-silenced cells may be due to reduced CDK2-dependent ATRIP Ser224 phosphorylation, which is required for G2 checkpoint maintenance . However, mutation of Ser224 does not fully phenocopy CINP silencing.
Interestingly, CINP also complexes with CEP152 (centrosomal protein 152 kDa) . Like ATR, CEP152 mutations cause Seckel syndrome [12,40]. Furthermore, evidence has linked mutations in pericentrin and CENPJ (centromere protein J) to Seckel syndrome as well [41,42]. CEP152, CENPJ and pericentrin all function at centrosomes, suggesting that one underlying cause of Seckel syndrome is a defect in centrosome function or duplication. In this model, ATR and CINP may participate in centrosome regulation. A large-scale screen for ATM and ATR substrates identified centrosome components, lending support to this idea . Furthermore, new data indicate that another centrosomal protein, CEP164, functions in ATR signalling . CEP164 was originally identified as a centriole appendage protein required for primary cilium function . CEP164 exists in both ATR and ATM complexes, as well as nucleotide excision repair protein complexes . Silencing CEP164 results in a G2 checkpoint defect, as well as CHK1 and RPA phosphorylation defects following UV damage. Whereas the interaction with ATR is not DNA-damage-regulated, ATR phosphorylates CEP164, and CEP164 localizes to nuclear foci in response to DNA damage. These linkages between ATR signalling and centrosome biology, although preliminary, warrant further investigation to understand both the mechanistic relationship and how defects in this pathway may cause Seckel syndrome.
The pro-apoptotic BH3 (Bcl-2 homology domain 3)-only protein BID also functions in the DDR and is an ATR and ATM substrate. Metaphase spreads from BID-deficient cells exhibit an increase in chromatid-type errors following mitomycin C treatment and increased sensitivity to DNA damage [47,48]. A new study determined that BID silencing results in less ATR–ATRIP association on chromatin following HU treatment and reduced CHK1 phosphorylation . Helix-4 of BID interacts with the coiled-coil domain of ATRIP, suggesting that BID may regulate ATR signalling via ATRIP. However, BID is not an essential gene, and its deletion phenotypes are not as severe as ATR or ATRIP deficiency. Therefore its contribution to ATRIP function might be context-dependent.
ATR RECRUITMENT TO SITES OF DNA DAMAGE
In addition to ATR stability, ATRIP is required for ATR recruitment to ssDNA gaps in the genome. Recognition of ssDNA by ATR–ATRIP occurs via an interaction between the acidic CRD (checkpoint recruitment domain) of ATRIP and a basic cleft in the ssDNA-binding protein RPA70 . Mutation of the ATRIP CRD as well as the basic cleft of RPA70 prevents ATR–ATRIP from binding to ssDNA [50,51]. However, an ATRIP mutant unable to bind RPA70 does not exhibit severe checkpoint signalling defects [26,50]. Mutation of the RPA70 basic cleft also does not fully compromise checkpoint signalling [52,53]. This suggests that there may be alternative, co-operating or semi-redundant mechanisms to localize ATR–ATRIP to DNA. Several new ATR-interacting proteins affect ATR recruitment to chromatin, and ATR can bind DNA directly. In this section, we describe how these interactions may co-operate with the canonical RPA-dependent mechanism of ATR–ATRIP recruitment.
CDC6 is an evolutionarily conserved DNA replication factor required to load the MCM (minichromosome maintenance) 2–7 protein complex on to replication origins . In addition to replication initiation, evidence for CDC6 function in the DDR comes from several experimental systems. Mutations in Schizosaccharomyces pombe CDC18CDC6 causes a mitotic checkpoint defect . Xenopus CDC6 is required for CHK1 phosphorylation in response to replication stress agents . In human cells, CDC6 overexpression in G2-phase results in a mitotic block that correlates with CHK1 activation , and silencing CDC6 in S-phase cells causes premature mitotic entry .
A challenge in interpreting many of these results is separating the function of CDC6 in replication initiation from its checkpoint signalling activity. After all, lack of initiation would lead to less checkpoint activation by agents that cause replication fork stalling. Two studies now provide some mechanistic insight into how CDC6 contributes to the DNA damage response via retention of ATR to chromatin.
In S. pombe, CDC18CDC6 and Rad3ATR increase on chromatin in response to replication stress . The increase in Rad3 on chromatin is lost in CDC18-deficient cells. Furthermore, Rad3 and CDC18 reside in the same complex that also contains Rad26ATRIP in cells treated with HU. Two-hybrid analysis and experiments with recombinant proteins produced in bacteria indicate a direct interaction between CDC18 and Rad26. Furthermore, Rad26 mutation abrogates CDC18 recruitment to chromatin and the CDC18–Rad3 interaction. Experiments in human cells confirmed that CDC6, ATR and ATRIP exist in a complex . Furthermore, chromatin retention of Xenopus ATR decreases with CDC6 depletion from extracts . It will be important to determine the molecular requirements for CDC6-mediated retention of ATR to chromatin. Ultimate proof that CDC6 functions upstream of ATR independently of its origin initiation activity requires the production of separation of function mutants.
FANCM is a gene mutated in patients with FA (Fanconi's anaemia) and helps tether an FA core complex to chromatin to regulate repair of DNA ICLs. However, unlike other FA proteins, FANCM is highly evolutionarily conserved, with orthologues found in all eukaryotes and even archaea. FANCM contains a conserved helicase domain with DNA translocase activity [61–63]. It associates with FAAP24 (FA-associated protein 24), which possesses DNA fork-structure-binding activities [64,65]. FANCM/FAAP24 localizes to chromatin and regulates fork progression and stability independently of the FA core complex [66–69].
FANCM/FAAP24 silencing abrogates the G2 checkpoint and reduces ATR signalling in response to many types of DNA lesions. FANCM potentially functions in ATR signalling at multiple steps in response to different damaging agents. For instance, in human cells, FANCM silencing reduced the amount of RPA–ssDNA induced by DNA ICLs . This is in contrast with HU, UV and camptothecin-induced RPA–ssDNA, which is actually increased in FANCM-silenced cells. Unlike HU and UV, DNA ICLs do not uncouple the polymerase and helicase to generate ssDNA, so FANCM/FAAP24 could be required to expose ssDNA in these contexts, placing the complex at the node of RPA–ssDNA generation. Whereas FANCM helicase activity is required for full checkpoint signalling in response to ICLs, it is not required for RPA–ssDNA formation as detected by RPA foci. Rather, FAAP24 DNA-binding activity is needed. It is still unclear how FAAP24 DNA binding mediates RPA–ssDNA formation. In response to other types of DNA damage, FANCM may function at the level of TOPBP1 recruitment to chromatin , since FANCM deletion causes reduced TOPBP1 binding following camptothecin treatment. Thus, depending on the context, FANCM may be important at several steps in the ATR pathway.
MutS and MutL
Activation of the ATR pathway depends on mismatch repair proteins in cells treated with base alkylation-inducing agents such as N-methyl-N′-nitro-N-nitrosoguanidine, but not replication fork stalling agents such as HU . There are two primary mechanistic explanations for the function of mismatch repair in ATR activation. Mismatch repair-dependent processing of the DNA may create RPA–ssDNA that then mediates ATR activation. Alternatively, there might be a direct function of specific mismatch repair proteins in ATR signalling mediated by direct protein–protein interactions. For example, the mismatch repair proteins could serve as a lesion recognition platform on which the signalling apparatus assembles (Figure 3).
Accumulating evidence supports the second model. MutSα associates with ATR, CHK1 and TOPBP1 [71–74], and MutLα interacts with TOPBP1 . Some of these interactions may be direct, although domain-mapping studies are incomplete, and interaction-deficient mutants have not been isolated. MutSα and MutLα regulate recruitment of ATR, CHK1 and TOPBP1 to chromatin in response to base damage . Importantly, RPA, Rad17 and Rad9 were not enriched on chromatin in these experiments and were not found to interact with mismatch repair proteins. Deletion of MSH2 also reduces ATR recruitment to damage sites after N-methyl-N-nitrosourea treatment, supporting a recruitment function for mismatch repair proteins in ATR activation .
These results suggest an RPA-independent mode of ATR activation in response to specific types of lesions detected by mismatch repair proteins. These findings fit with observations that ATR can be activated in the absence of a direct RPA–ATRIP interaction [26,50]. This model makes several testable predictions. First, the ATRIP-CRD mutation, which cannot interact with RPA , should have no effect on ATR chromatin association following base damage. Secondly, Rad17 or Rad9 silencing would not affect ATR signalling and recruitment of TOPBP1 and CHK1 after base damage. Finally, it should be possible to identify separation of function mutations in ATR or, more likely, ATRIP that block ATR activation by N-methyl-N′-nitro-N-nitrosoguanidine, but not activation by HU.
FLAG–ATR purified from mammalian cells can interact with duplex DNA and UV-damaged DNA . Additionally, linearized plasmid stimulates ATR activity in vitro, and this stimulation increases when the DNA is damaged by UV or benzo[a]pyrene diol epoxide [76,77]. This implies that ATR binding to damaged duplex DNA occurs in a manner distinct from the RPA–ssDNA binding mode (Figure 3). Yet ATR lacks a known DNA-binding domain, and DNA-binding activity has not been localized to any specific ATR fragment. A clue may come from research on the Bacillus cereus AlkD glycosylase. Rubinson et al.  reported recently this glycosylase binds alkylated and abasic DNA via its HEAT repeats. The HEAT repeats create a concave surface lined with positively charged residues that mediate electrostatic interactions with the phosphoribose DNA backbone. The lesion itself is not recognized directly. Instead, AlkD recognizes helical distortion created when the damaged base is flipped out into solution. These findings suggest the possibility that ATR binds damaged DNA via its HEAT repeats. This mechanism of DNA binding would explain how multiple types of DNA lesions could be recognized by ATR. Structural studies of DNA-PK support the idea that its HEAT repeats can bind DNA [79,80]. Unfortunately, testing this speculative model will be difficult, given the slow progress in creating soluble recombinant forms of ATR in sufficient quantities for structural studies.
Recruitment of ATR–ATRIP to DNA lesions or stalled forks is not sufficient for checkpoint signalling. The ATR-activation process is not well understood, but it requires the ATR activator TOPBP1, which is recruited independently of ATR–ATRIP localization. A region of TOPBP1 termed the AAD (ATR-activating domain) binds surfaces on both ATR and ATRIP , and this domain is sufficient to stimulate ATR kinase activity both in vitro and in vivo . Mapping of the AAD-binding surface on ATR delineated a regulatory domain called the PRD (PIKK-regulatory domain) . The PRD resides between the ATR kinase domain and the FATC domain, and mutation of this region results in loss of ATR activation by TOPBP1 as well as checkpoint and viability defects. Interestingly, this region of the other PIKKs, including ATM and DNA-PK, is also important for their activation [30,81]. The PRD of ATM contains a critical lysine and cysteine residue that are acetylated or oxidized respectively [81,82]. Acetylation by TIP60 [Tat (transactivator of transcription)-interactive protein 60 kDa] activates ATM, and oxidation provides a mechanism of regulating ATM by oxidative stress independently of DSBs. Mutations in the PRD of DNA-PK also interfere with its activation . It should be noted that the PRD region is not the same as the FATC domain. The FATC domain is defined by sequence similarity among the PIKK family of kinases. In contrast, the PRD of each PIKK is unique, which may allow different inputs to activate each PIKK .
TOPBP1-mediated activation of ATR is conserved to budding yeast. Saccharomyces cerevisiae DPB11TOPBP1 stimulates MEC1ATR kinase activity in vitro [83,84]. Similar to TOPBP1, a discrete region of the C-terminus of DPB11 interacts with MEC1ATR and DDC2ATRIP and is sufficient to activate MEC1. Additional proteins, such as the checkpoint clamp protein DDC1, can also serve as direct ATR activators in the budding yeast system [85,86]. Whether this mechanism is conserved in other organisms is unknown.
A thorough understanding of ATR activation mechanisms will require both structural studies and reconstitution of the activation steps in vitro. The Sancar group made an important advance in this area when they partially reconstituted ATR activation using purified RPA, ATR–ATRIP and TOPBP1 proteins along with DNA . Interestingly, they reported that only native purified ATR–ATRIP and not overexpressed versions of these proteins were a good source for their assays. This might imply that overexpressed protein lacks some regulatory partners or post-translational modifications necessary for the RPA–ssDNA and TOPBP1-dependent regulation of ATR.
It is becoming increasingly clear that, like ATR–ATRIP recruitment, TOPBP1 recruitment may occur through multiple mechanisms possibly depending on the DNA-damage context. One mechanism of TOPBP1 recruitment involves the 9-1-1 checkpoint clamp complex. The RFC (replication factor C)-like clamp loader containing Rad17 loads the 9-1-1 complex on to the junction of double- and single-stranded DNA [88–90]. This loading is specific to a 5′-recessed junction perhaps due to the interaction of Rad9 with the 70N domain of RPA . Interaction between the phosphorylated tail of Rad9 and BRCT (BRCA1 C-terminal) repeats 1–2 of TOPBP1 [91–93] position TOPBP1 for ATR activation. Importantly, 9-1-1 and TOPBP1 recruitment occurs independently of ATR–ATRIP [94,95]. The independent recruitment of ATR and its protein activator TOPBP1 builds in an important regulatory feature recently described as the ‘two-man rule’ for ATR activation . Requiring multiple complexes to separately sense a DNA lesion or stalled fork prevents precocious activation of the checkpoint.
Yan and Michael  reported recently that TOPBP1 can be recruited to chromatin before Rad9 in Xenopus extracts. Furthermore, Rad9 recruitment required TOPBP1. One possible model to explain these results would be that, at least under some circumstances, the Rad9–TOPBP1 interaction is a mechanism of signal amplification instead of initiation. A critical unanswered question, however, is how TOPBP1 recognizes damaged DNA and stalled replication forks without Rad9.
TOPBP1 can bind ssDNA directly in reconstituted in vitro systems. However, if RPA is pre-loaded on to the ssDNA, TOPBP1 association with RPA–ssDNA requires the presence of ATRIP . Given that RPA has a much higher affinity for ssDNA than TOPBP1, it seems unlikely that a TOPBP1–ssDNA interaction would be sufficient for recruitment. An interaction between the TOPBP1 AAD and ATRIP mediates ATR activation , but the recruitment of TOPBP1 to chromatin requires different regions of TOPBP1 and not its AAD [97,98]. TOPBP1 has multiple additional binding partners, including treslin, CtIP (C-terminal-binding protein-interacting protein), BACH1 (BRCA1-associated C-terminal helicase 1) and the MRN (Mre11, Rad50 and Nbs1) complex [99–103]. Each of these may contribute to TOPBP1 and ATR signalling regulation in specific circumstances. For example, a TOPBP1–BACH1 interaction contributes to the exposure of ssDNA at stalled replication forks . However, further research is necessary to understand how TOPBP1 initially recognizes the damaged fork.
TOPBP1-mediated activation of ATR and post-translational modifications
Mechanistic information on how TOPBP1 stimulates ATR kinase activity is lacking. It is postulated that TOPBP1 binding to ATR induces a conformational change that increases substrate affinity for the kinase. This is based on the observation that TOPBP1 greatly reduces the Km of ATR for its substrates . In this model, ATR would only be active when bound directly by TOPBP1. This is consistent with an inability to purify an active ATR protein from damaged cells. Such purification attempts may fail because TOPBP1 does not remain bound to the complex. This model would also imply that ATR activation may not be accompanied by a post-translational modification that is sufficient to stabilize the activated form of the kinase.
ATR is phosphorylated in cells and can autophosphorylate in vitro. An antibody against one phosphorylation site (Ser428) is commercially available, and some reports have used it as a marker of ATR activation. However, this site is unlikely to be an autophosphorylation site, and it is not clear whether mutation of the site to alanine has any impact on ATR activation or function. Thus it is questionable whether antibodies against this site provide a meaningful description of ATR activity. Currently, the best measure of ATR activation is CHK1 phosphorylation on the ATR-dependent residues Ser317 and Ser345 [104,105]. Of course, this is at best an indirect measure of ATR activity. CHK1 is one of several hundreds of ATR substrates. Unlike other ATR substrates, its phosphorylation by ATR has unique requirements for other proteins, including claspin . Thus identifying a regulatory ATR autophosphorylation site would provide a much-needed tool for ATR studies and could be used as a potential biomarker in clinical development of ATR inhibitors for cancer therapy.
Upon activation, ATR co-ordinates cell cycle checkpoints, replication fork stability and restart, and origin firing. However, few studies have elucidated specific mechanisms through which ATR elicits these responses. The best-characterized mechanisms are the checkpoint responses mediated by ATR activation of CHK1. These include the G2 checkpoint that prevents entry into mitosis in the presence of damaged DNA via regulation of the CDC25 phosphatase. Since the CHK1-dependent ATR pathway is the subject of many reviews (e.g. [4,107]), we focus the following discussion on other ATR signalling activities.
ATR-dependent regulation of replication origin activity
One of the well-established activities of ATR is to regulate origin firing. Evidence exists for both positive and negative regulation of origin firing by ATR. For example, delaying late origin firing at least partly mediates the S-phase checkpoint . However, replication-associated DNA damage that stalls replication forks also can induce nearby replication origins to fire in an apparent attempt to complete DNA synthesis independently of the damaged fork [109–111]. A recent study in S. cerevisiae suggests that MEC1ATR also has a function during normal replication to promote replication initiation . The mechanisms underlying these ATR activities are complex and may differ between organisms. However, we are beginning to obtain some important insights into these processes.
ATR represses origin firing in vertebrate cells at least partly by regulating chromatin structure around origins. Specifically, ATR regulates the lysine methyltransferase MLL . MLL methylates histone H3 on Lys4 (H3K4) and functions in embryogenesis and cell fate determination, in addition to cell-cycle regulation . MLL-deficient cells exhibit chromatid-type errors and S-phase checkpoint defects. MLL activity is tightly controlled by its abundance. It is degraded in S- and M-phase by the SCFSKP2 and APCCDC20 complexes respectively , and overexpression of MLL perturbs S-phase progression. ATR phosphorylates MLL in response to DNA damage in S-phase . This phosphorylation prevents MLL from interacting with SKP2, thereby stabilizing it. Increased MLL abundance leads to increased H3 methylation at origins. Importantly, the replication initiation protein CDC45 binds directly to H3, but not methylated H3K4me3. Thus, in response to damage during S-phase, ATR phosphorylates and stabilizes MLL, which prevents CDC45 loading on to origins by methylating H3K4 (Figure 4).
Paradoxically, ATR also promotes origin firing in some circumstances. First, there are many more licensed replication origins than are used in each round of replication. The extra origins provide a resource to use to complete DNA syntheses when there is stalling of elongating replication forks [109–111]. ATR-dependent phosphorylation of MCM2 promotes the recruitment of PLK1 (Polo-like kinase 1) [116–118]. At least locally, this has the effect of allowing origins to fire perhaps through localized differences in CHK1 signalling. Evidence now indicates that these localized differences specifically inhibit activation of new replication factories while allowing dormant origins to fire within pre-existing factories in an ATR–CHK1-dependent manner . A second activity of ATR in promoting replication initiation also occurs through MCM protein phosphorylation. Phosphorylation of the MCM proteins by the replication-promoting DDK (DBF4–CDC7 kinase) initiates origin firing . However, DDK often requires a priming phosphorylation for it to recognize its substrates. The S. cerevisiae ATR protein catalyses some of these priming phosphorylation events .
The discovery of these ATR-dependent activities to regulate origin firing provides exciting insights into ATR function. However, they also raise many new questions. How can ATR both promote and inhibit origin firing? What determines the local and global response to ATR activation? Why would a checkpoint kinase known to slow DNA synthesis and cell-cycle progression be involved in priming events on pre-replication complexes to promote initiation? Are these mechanisms of ATR function conserved in all eukaryotic organisms or has evolution made use of the ATR kinase in different ways in different organisms? On the basis of the rapid pace of research in this area, we can hopefully anticipate answers to many of these questions in the near future.
Cross-talk between transcription and the replication checkpoint
Transcription and replication are intimately linked if for no other reason than they both must make use of the same DNA template. Co-ordination of transcription (and additional associated RNA-processing activities) and replication is necessary to prevent fork stalling at active transcription units. Indeed, silencing many RNA-processing enzymes by RNAi (RNA interference) causes DNA damage partly due to formation of R-loop intermediates where RNA is bound to the DNA duplex . These may be processed directly to cause DNA breakage or may serve as obstacles for elongating DNA polymerases. In the most highly transcribed regions of DNA and in ribosomal gene clusters, programmed origins and replication pause sites assure that replication and transcription machinery do not make head-on collisions . We will not attempt to review all the literature on how RNA-processing activities cross-talk with the ATR-dependent replication checkpoint. However, we offer two examples to illustrate that the cross-talk may be more direct than simply collisions of separate RNA and DNA-processing machineries.
CDK9 regulates transcription by phosphorylating the C-terminal tail of RNA polymerase II. It performs this activity as part of the pTEFb (positive transcription elongation factor B) complex containing the regulatory cyclin T1 or T2 [123,124]. Interestingly, CDK9 regulates the ATR-dependent response to stalled replication forks independently of its pTEFb activity . In this case, CDK9 complexes with cyclin K, and this complex is essential for the resumption of DNA synthesis following a challenge with replication-fork-stalling agents such as HU or aphidicolin. CDK9 can be found in complexes with ATR–ATRIP, but does not appear to act upstream of ATR, since ATR substrate phosphorylation is not perturbed in CDK9- or cyclin K-silenced cells. These data suggest that CDK9–cyclin K may act downstream of ATR to regulate replication fork stability. Its activities in replication require an intact CDK9 kinase domain. Therefore identifying the substrates of CDK9–cyclin K will be essential to understand its function. Notably, this activity in the DDR appears to be evolutionarily conserved, since yeast CDK9–cyclin proteins also participate in the DDR .
A second example of ATR cross-talk with RNA-processing machinery is the splicing factor CDC5L. CDC5L is part of a conserved mRNA splicing complex, which contains PSO4/PRP19, SPF27 and PLRG1 . Silencing CDC5L causes sensitivity to replication stress agents and defects in ATR-dependent checkpoint signalling . The simplest explanation would be an indirect effect of splicing problems on production of ATR or its regulatory partners. Surprisingly, further experiments suggested a more direct function when CDC5L was found to interact with ATR. As yet, the data are too preliminary to conclude how CDC5L actually regulates ATR signalling. Whereas deleting an ATR interaction domain on CDC5L causes DDR defects, it is not clear whether this deletion actually separates its DDR and RNA-processing functions. Nonetheless, these data are intriguing, especially in the light of identification of multiple RNA-processing proteins in genetic and biochemical screens looking for new DDR factors [38,43,121].
Some 15 years of ATR research since the gene was first cloned has established the biological importance of ATR in DNA replication and the DDR. A mechanistic understanding of ATR activation has progressed dramatically in this time, but much is still unclear. Regulation of ATR recruitment to sites of DNA damage and the mechanism of activation defy simple linear models. The discovery of multiple mechanisms of ATR regulation that do not fit neatly into the canonical signalling pathway suggests that context of the activation signal is important. Some of these mechanisms may function in response to specific lesion types, whereas others may be more general modes of regulation that potentiate or amplify signalling without being essential for all ATR function.
The number of ATR-interacting proteins and substrates is steadily increasing. Now that ATR signalling has been partially reconstituted in vitro, systematic examination of these new factors biochemically is feasible. TOPBP1-mediated activation of ATR is perhaps the most important step in the regulatory pathway, but the lack of high-resolution ATR structural information stymies mechanistic understanding of this activation step. Finally, clues found in the last couple of years hint at a broad and complex function for ATR in many aspects of cellular physiology. Much remains to be learned about the mechanisms through which ATR signalling regulates genome maintenance.
Our work on ATR is supported by the National Institutes of Health [grant number CA102729 (to D.C.)].
Abbreviations: 9-1-1, RAD9–HUS1–RAD1; AAD, ATR-activating domain; ATM, ataxia telangiectasia mutated; ATR, ATM- and Rad3-related; ATRIP, ATR-interacting protein; BACH1, BRCA1-associated C-terminal helicase 1; CDK, cyclin-dependent kinase; CENPJ, centromere protein J; CEP, centrosomal protein; CHK1, checkpoint kinase 1; CINP, CDK2-interacting protein; CRD, checkpoint recruitment domain; DDK, DBF4–CDC7 kinase; DDR, DNA-damage response; DNA-PK, DNA-dependent protein kinase; DSB, double-strand break; FA, Fanconi's anaemia; FAAP24, FA-associated protein 24; HSP90, heat-shock protein 90; HU, hydroxyurea; ICL, interstrand cross-link; MCM, minichromosome maintenance; PIKK, phosphoinositide-3-like kinase kinase; PLK1, Polo-like kinase 1; PRD, PIKK regulatory domain; pTEFb, positive transcription elongation factor B; RPA, Replication Protein A; ssDNA, single-stranded DNA; TOPBP1, topoisomerase-binding protein 1
- © The Authors Journal compilation © 2011 Biochemical Society